托法替尼
医学
溃疡性结肠炎
贾纳斯激酶
Janus激酶抑制剂
炎症性肠病
药理学
免疫学
内科学
疾病
细胞因子
类风湿性关节炎
作者
Brittany N. Palasik,Hongmei Wang
标识
DOI:10.1177/0897190020953019
摘要
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) characterized by chronic gastrointestinal inflammation. In most patients, the disease cycles through periods of remission and exacerbations. The complex etiology involves multiple factors including environmental, genetic, and immune causal elements. Janus Kinase (JAK) family is an essential component of a cytokine-signaling cascade partially responsible for the pathogenesis of UC. Treating UC presents difficulties despite various therapeutic options. Medications that block the JAK-signaling pathway can interfere with the inflammatory pathway of UC and possibly reduce symptoms and frequency of exacerbations. Tofacitinib is an oral pan-JAK inhibitor, primarily of JAK1 and JAK3, that was recently approved by the Food and Drug Administration (FDA) for the chronic treatment of UC in 2018. The following review describes the newly approved Janus kinase inhibitor, tofacitinib, including its pharmacokinetic properties, efficacy and safety data, and potential place in therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI